The ELAD trial is among the first multicenter randomized, double-blind, placebo-controlled studies to test a GLP-1 receptor agonist for disease modification in Alzheimer’s disease [114]. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.